Skip to content

Insulet PODD Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Medtronic logo
MedtronicMDT
AptarGroup logo
AptarGroupATR
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Abbott logo
AbbottABT
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's common stock, shares authorized (in shares)?
Insulet (PODD) reported common stock, shares authorized (in shares) of $100M in Q1 2026.
How has Insulet's common stock, shares authorized (in shares) changed year-over-year?
Insulet's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Insulet's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Insulet's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.